CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus
You-Cheol Hwang, Ji Eun Jun, In-Kyung Jeong, Kyu Jeung Ahn, Ho Yeon Chung
Diabetes Metab J. 2019;43(5):582-589.   Published online January 16, 2019
DOI: https://doi.org/10.4093/dmj.2018.0124

Excel Download

Letter: Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J2019;43:582–9)
Diabetes & Metabolism Journal. 2019;43(6):909   Crossref logo
Link1 Link2 Link3

Response: Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2019;43:582–9)
Diabetes & Metabolism Journal. 2019;43(6):915   Crossref logo
Link1 Link2 Link3

Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus
Diabetes & Metabolism Journal. 2019;43(5):582   Crossref logo
Link1 Link2 Link3

Lipid-Altering Efficacy of Ezetimibe/Simvastatin 10/20 mg Compared to Rosuvastatin 10 mg in High-Risk Patients with and without Type 2 Diabetes Mellitus Inadequately Controlled Despite Prior Statin Monotherapy
Cardiovascular Therapeutics. 2010;30(2):61-74   Crossref logo
Link1 Link2

Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study
International Journal of Clinical Practice. 2009;63(4):547-559   Crossref logo
Link1 Link2

MS391 EFFICACY OF SWITCHING FROM STATIN MONOTHERAPY TO EZETIMIBE/SIMVASTATIN 10/20 mg VERSUS ROSUVASTATIN 10 mg IN HIGH-RISK PATIENTS ANALYZED BY BASELINE LDL-C
Atherosclerosis Supplements. 2010;11(2):189   Crossref logo
Link1 Link2

Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study
Atherosclerosis. 2014;232(1):86-93   Crossref logo
Link1 Link2

Review of efficacy of rosuvastatin 5 mg
International Journal of Clinical Practice. 2005;59(1):92-101   Crossref logo
Link1 Link2

Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk patients with and without metabolic syndrome
Diabetes and Vascular Disease Research. 2011;8(4):262-270   Crossref logo
Link1 Link2 Link3

PCV2 CLINICAL EXPERIENCE IN DYSLIPIDEMIC PATIENTS TREATED EITHER WITH ROSUVASTATIN 10 MG/DAY OR EZETIMIBE/SIMVASTATIN 10/20 MG/DAY IN MEXICO CITY. A RETROSPECTIVE ANALYSIS
Value in Health. 2007;10(3):A37   Crossref logo
Link1 Link2